Clinical Trials in Norway / NCT07332260
Recruiting
Phase 1
Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study
NCT07332260 · tracked via the Priya Life Science Norway tracker
Condition(s) studied
Alzheimer s DiseaseFaecal Microbiota Transplantation (FMT)
Investigational drug(s) / intervention(s)
Biological: Preprocessed thawed donor FMT
Biological: Preprocessed thawed donor FMT: Biological: Preprocessed FMT solution is administered to the right side of the colon during a colonoscopy.
Study summary
The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.
Eligibility
Inclusion Criteria:
* Alzheimer's dementia mild to moderate stage
* Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024)
* Capable of giving informed consent
Exclusion Criteria:
* Contraindications for colonoscopy examination
* Contraindications for Magnetic Resonance Imaging (MRI)
* Life expectancy \< 1 year
* Clinical frailty scale 7 or more
* History of seizure disorder
* History of brain tumour or intracranial bleed
* Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder
* Alcohol or substance abuse
* Decompensated heart disease
* Malignancy
* Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin)
* Pregnant or planning pregnancy
* Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy
* Status after colectomy or hemicolectomy
* Inflammatory bowel disease
* Immunocompromised individual
* Receiving biological/antibody treatment
Primary outcome measure(s)
- Incidence of treatment-related adverse events and serious adverse events. [Safety] — From baseline to 3 months after faecal microbiota transplantation
Incidence of adverse events (AE) and serious adverse events (SAE). AE and SAE are evaluated by review of the medical record, questions of AE and SAE in person or by telephone, and AE and SAE forms. - Rate of participant recruitment [Feasibility] — 1 year
Number of weeks needed to include ten participants for study intervention group - Number participants that complete colonoscopy [Feasibility] — 1 year
Number of participants that complete colonoscopy - Time used per intervention [Feasibility] — 1 year
Time given in hours and minutes of total time used for intervention per participant including colonoscopy and faecal microbiota transplantation. - Number that meet study eligibility [Feasibility] — 1 year
Number of participants who are screened for study eligibility. Number who meet inclusion and exclusion criteria. - Number that complete study [Feasibility] — Baseline and 3 months after study intervention
Proportion of participants enrolled that complete the study follow-up. - Engraftment of faecal microbiota transplantation (FMT) — baseline and 3 months after study intervention
Comparison of the taxonomic composition of the microbiome in participants faecal samples at baseline and 3 months after FMT, with donor faecal sample. Metagenomic sequencing of faecal samples will be used.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University Hospital of North Norway, Tromsø | Tromsø | Troms | Recruiting |
More University Hospital of North Norway trials in Norway
Health in Work - a Measure for Increased Coping and Work Inclusion
Active, not recruiting
Testing a Group Memory Training Program for People With Brain Injuries
Enrolling by invitation
Artificial Intelligence Enabled Decision Support for Selection of Patients for Lumbar Spine Surgery
Starting soon
Donor Versus Autologous Fecal Microbiota Transplantation for Irritable Bowel Syndrome
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07332260 on ClinicalTrials.gov ↗ ← All trials in Norway